Drugs / Bosentan
Bosentan
also known as
Tracleer · Bosentan: Tracleer · Anhydrous bosentan · Bosentan (as monohydrate) · Bosentan anhydrous · Bosentan hydrate · Bosentan monohydrate · BOSENTAN SODIUM · +2 more
Regulatory milestones approvals, filings & regulatory actions · 8 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed pulmonary arterial hypertension 1 milestone | |||||
| Filed | US (FDA) | — | pulmonary arterial hypertension | 2019-06-04 | “submission of an Abbreviated New Drug Application (ANDA) with Para IV certification with U.S. Food and Drug Administration (FDA) for the generic version of Bosentan” natcopharma.co.in ↗ |
| Approved Indication not stated 3 milestones | |||||
| Label expansions (5) | US (FDA) | TRACLEER | — | 2003-10-06 – 2012-10-04 | fda.gov ↗ |
| Approved | EU (EMA) | Tracleer | — | 2002-05-14 | europa.eu ↗ |
| Approved | US (FDA) | TRACLEER | — | 2001-11-20 | fda.gov ↗ |
Trials 85 · started per year
today
US approved 2001
EU approved 2002
1
5
5
5
12
6
4
5
5
9
2
4
1
3
2
1
1
1
1
2
4
2
2
2
2001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT05518422 | Feb 2024 | dysautonomia, obesity disorder | University of Missouri-Columbia | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 0 | NCT05146089 | Dec 2016 → Sep 2018 | sleep apnea syndrome | University of Missouri-Columbia | Completed | No outcome recorded |
| Phase 0 | NCT01100736 | Jan → Sep 2009 | isoproterenol-mediated vasodilatation, pulmonary arterial hypertension | University of Edinburgh | Completed | No outcome recorded |
| Phase 115 trials | ||||||
| Phase 1 | NCT07649941 | Jun → Jul 2026 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT07081932 | Aug → Sep 2025 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT07838987 | Dec 2023 → Jun 2026 | — | Terns, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05723874 | Mar → May 2023 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT05657613 | Jan → Jun 2023 | — | CTI BioPharma | Completed | No outcome recorded |
| Phase 1 | NCT04158635 | Sep 2021 → Mar 2027 | malignant pancreatic neoplasm | City of Hope Medical Center | Suspended | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT04068272 | Sep 2019 → May 2022 | diabetes mellitus | Retinset SL | Completed | No outcome recorded |
| Phase 1 | NCT04991207 | Feb → May 2018 | pulmonary arterial hypertension | Bial - Portela C S.A. | Completed | No outcome recorded |
| Phase 1 | NCT02667704 | Feb → Mar 2016 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT01929213 | Aug → Nov 2013 | — | Dong-A Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT01864863 | Apr → May 2013 | pulmonary arterial hypertension | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 1 | NCT00701597 | Apr → Sep 2007 | glaucoma | Medical University of Vienna | Completed | No outcome recorded |
| Phase 1 | NCT00432978 | Jul 2006 → Feb 2007 | altitude sickness, pulmonary hypertension | VA Loma Linda Health Care System | Completed | No outcome recorded |
| Phase 1 | NCT00260819 | Jan 2006 → Apr 2008 | pulmonary hypertension owing to lung disease and/or hypoxia | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 1 | NCT00223717 | Jan 2001 → Jan 2017 | hypertensive disorder | Vanderbilt University | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT01270750 | Dec 2010 → Jun 2011 | congestive heart failure, mitral valve stenosis, pulmonary hypertension, rheumatic fever | General Hospital of Chalkida | Unknown | No outcome recorded |
| Phase 1/2 | NCT00226889 | Jan 2005 → Jan 2009 | systemic sclerosis | Rikshospitalet University Hospital | Terminated | No outcome recorded Stop: Enrollment |
| Phase 215 trials · 1 met primary · 2 missed | ||||||
| Phase 2 | NCT06957002 | Jun 2026 → Jun 2029 expected | temporal arteritis | Assistance Publique - Hôpitaux de Paris | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06887062 | Mar 2025 → Jul 2027 expected | Takayasu arteritis, temporal arteritis | University of Edinburgh | Recruiting | No outcome recorded |
| Phase 2 | NCT04388124 | Oct 2021 → Aug 2026 overdue | resistant hypertension | University Hospital, Rouen | Recruiting | No outcome recorded |
| Phase 2 | NCT02317679 | Apr → Sep 2014 | — | Centre Hospitalier Universitaire de Nice | Completed | No outcome recorded |
| Phase 2 | NCT02093195 | Dec 2013 → Dec 2015 | chronic obstructive pulmonary disease | Air Force Military Medical University, China | Unknown | No outcome recorded |
| Phase 2 | NCT01617746 | Nov 2012 → May 2014 | asthma | University of Glasgow | Unknown | No outcome recorded |
| Phase 2 | NCT01241383 | Dec 2010 → Oct 2015 | scleroderma | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 2 | NCT01662037 | Jan 2010 → Sep 2011 | congenital heart defects, multiple types, univentricular heart | Shanghai Jiao Tong University School of Medicine | Completed | No outcome recorded |
| Phase 2 | NCT00926627 | Apr 2009 → Mar 2010 | pulmonary hypertension, sarcoidosis | Daniel Doberer | Terminated | No outcome recorded |
| Phase 2 | NCT00815347 | Dec 2008 → Sep 2010 | asthma | UConn Health | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00777985 | Dec 2007 → Jan 2012 | hypertensive disorder, obstructive sleep apnea syndrome | University Hospital, Grenoble | Completed | Missed primary |
| Phase 2 | NCT01357109 | Nov 2007 → Apr 2010 | type 2 diabetes mellitus | Karolinska Institutet | Completed | Met primary |
| Phase 2 | NCT00377455 | Sep 2006 → Sep 2009 | pulmonary hypertension, systemic sclerosis | Georgetown University | Terminated | No outcome recorded |
| Phase 2 | NCT00318175 | Jun 2006 → May 2007 | cutaneous sclerosis, systemic sclerosis | Heinrich-Heine University, Duesseldorf | Completed | No outcome recorded |
| Phase 2 | NCT01009177 | Sep 2005 → Feb 2008 | melanoma | Actelion | Completed | Missed primary |
| Phase 2/35 trials · 2 missed | ||||||
| Phase 2/3 | NCT06432452 | Nov 2024 → Jun 2026 overdue | coronary vasospasm | Radboud University Medical Center | Enrolling by invitation | No outcome recorded |
| Phase 2/3 | NCT01352065 | Jan 2011 → Dec 2012 | pulmonary hypertension | Center for Health Sciences, Serbia | Completed | No outcome recorded |
| Phase 2/3 | NCT00319033 | Jul 2004 → Feb 2006 | interstitial lung disease, systemic sclerosis | Actelion | Completed | No outcome recorded |
| Phase 2/3 | NCT00071461 | Aug 2003 → Sep 2005 | idiopathic pulmonary fibrosis | Actelion | Completed | Missed primary |
| Phase 2/3 | NCT00070590 | Jul 2003 → Sep 2005 | pulmonary fibrosis, systemic sclerosis | Actelion | Completed | Missed primary |
| Phase 322 trials · 1 met primary · 3 missed | ||||||
| Phase 3 | NCT03841734 | Feb 2020 → Jul 2023 | arteritis, blindness (disorder) | Centre Hospitalier Universitaire de Nice | Completed | No outcome recorded |
| Phase 3 | NCT02377271 | Aug 2015 → Dec 2023 | non-arteritic anterior ischemic optic neuropathy | University Hospital, Grenoble | Unknown | No outcome recorded |
| Phase 3 | NCT01712997 | Sep 2012 → Sep 2014 | pulmonary arterial hypertension | Air Force Military Medical University, China | Unknown | Met primary |
| Phase 3 | NCT01389856 | Dec 2011 → Dec 2013 | pulmonary hypertension, neonatal | Actelion | Terminated | Missed primary |
| Phase 3 | NCT01392469 | Apr 2011 → Oct 2012 | pulmonary arterial hypertension | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01338415 | Mar 2011 → Aug 2014 | pulmonary arterial hypertension | Actelion | Completed | No outcome recorded |
| Phase 3 | NCT01223352 | Mar 2011 → Apr 2013 | pulmonary arterial hypertension | Actelion | Completed | No outcome recorded |
| Phase 3 | NCT00864201 | Apr 2009 → Apr 2010 | connective tissue disorder, pulmonary hypertension | Hamilton Health Sciences Corporation | Unknown | No outcome recorded |
| Phase 3 | NCT00638131 | Jan 2009 → Mar 2010 | type 2 diabetes mellitus | University of Montreal Hospital Centre (CHUM) | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT00631475 | Apr 2008 → Apr 2010 | idiopathic pulmonary fibrosis | Actelion | Completed | No outcome recorded |
| Phase 3 | NCT00391443 | Feb 2007 → Feb 2010 | idiopathic pulmonary fibrosis | Actelion | Completed | Missed primary |
| Phase 3 | NCT00313196 | Apr 2006 → Aug 2007 | pulmonary hypertension | Actelion | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT00310830 | Mar 2006 → Aug 2007 | pulmonary hypertension | Actelion | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT00360087 | Mar 2006 → Aug 2007 | pulmonary hypertension, sickle cell disease | Actelion | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT00303004 | Mar 2006 → Jan 2008 | Eisenmenger syndrome | Rigshospitalet, Denmark | Completed | Missed primary |
| Phase 3 | NCT00319111 | Jan 2006 → Feb 2009 | pulmonary hypertension | Actelion | Completed | No outcome recorded |
| Phase 3 | NCT00313222 | Oct 2005 → Feb 2007 | chronic thromboembolic pulmonary hypertension | Actelion | Completed | No outcome recorded |
| Phase 3 | NCT00319020 | Aug 2005 → Oct 2011 | pulmonary arterial hypertension | Actelion | Completed | No outcome recorded |
| Phase 3 | NCT00319267 | May 2005 → Dec 2006 | pulmonary arterial hypertension | Actelion | Completed | No outcome recorded |
| Phase 3 | NCT00319696 | Jul 2004 → Jan 2009 | — | Actelion | Completed | No outcome recorded |
| Phase 3 | NCT00091715 | Apr 2004 → Nov 2006 | pulmonary hypertension | Actelion | Completed | No outcome recorded |
| Phase 3 | NCT00077584 | Oct 2003 → Mar 2005 | systemic sclerosis | Actelion | Completed | Mixed |
| Phase 415 trials · 1 missed | ||||||
| Phase 4 | NCT03229694 | Aug 2017 → Apr 2018 | hypertensive disorder | Xuzhou Medical University | Unknown | No outcome recorded |
| Phase 4 | NCT02480335 | Jun 2015 → Jul 2018 | systemic sclerosis | University Medical Center Groningen | Completed | No outcome recorded |
| Phase 4 | NCT03236818 | May 2013 → Sep 2017 | pulmonary arterial hypertension | Amsterdam UMC, location VUmc | Unknown | No outcome recorded |
| Phase 4 | NCT01779596 | May 2011 → Dec 2013 | type 2 diabetes mellitus | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT01395732 | Mar 2011 → Nov 2012 | systemic sclerosis | Actelion | Completed | No outcome recorded |
| Phase 4 | NCT01779609 | Apr 2010 → Dec 2013 | type 2 diabetes mellitus | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00679068 | May 2008 → Dec 2012 | pulmonary hypertension | IRCCS Azienda Ospedaliero-Universitaria di Bologna | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT00625469 | Oct 2007 → Jun 2009 | idiopathic pulmonary fibrosis, pulmonary arterial hypertension | Rajan Saggar | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT00433329 | Mar 2007 → May 2010 | pulmonary arterial hypertension | Actelion | Completed | No outcome recorded |
| Phase 4 | NCT00595049 | May 2006 → Dec 2008 | pulmonary hypertension | Actelion | Completed | No outcome recorded |
| Phase 4 | NCT00303459 | May 2006 → Dec 2013 | pulmonary arterial hypertension | Actelion | Completed | Missed primary |
| Phase 4 | NCT00266162 | Aug 2004 → Feb 2008 | Eisenmenger syndrome | Competence Network for Congenital Heart Defects | Completed | No outcome recorded |
| Phase 4 | NCT00367770 | Jan 2004 → Dec 2005 | pulmonary arterial hypertension | Actelion | Completed | No outcome recorded |
| Phase 4 | NCT00317486 | Sep 2003 → Apr 2005 | Eisenmenger syndrome | Actelion | Completed | No outcome recorded |
| Phase 4 | NCT00082186 | Jul 2003 → Feb 2007 | pulmonary arterial hypertension | Actelion | Completed | No outcome recorded |
| Phase not applicable8 trials · 2 met primary | ||||||
| — | NCT07670091 | Jul 2023 → Jul 2025 overdue | coronary microvascular disorder, nonobstructive coronary artery disease | Liverpool University Hospitals NHS Foundation Trust | Active not recruiting | No outcome recorded |
| — | NCT02116335 | Jun 2015 → Dec 2025 overdue | hypertensive disorder | Augusta University | Active not recruiting | No outcome recorded |
| — | NCT01184404 | Sep 2011 → Jul 2016 | congenital heart disease | Berto J Bouma | Unknown | No outcome recorded |
| — | NCT01548950 | Sep 2011 → Jan 2014 | congenital heart disease, pulmonary arterial hypertension | University of Sao Paulo General Hospital | Completed | No outcome recorded |
| — | NCT00989911 | May 2010 → Mar 2013 | congenital heart disease | University of California, Los Angeles | Completed | No outcome recorded |
| — | NCT01738542 | Apr 2009 → Nov 2010 | peripheral arterial disease | Hospital Universitario Getafe | Completed | Met primary |
| — | NCT00909337 | Jan 2008 → Jun 2010 | pulmonary hypertension, systemic sclerosis | Medical University of Graz | Completed | Met primary |
| — | NCT01721564 | Apr 2006 → May 2009 | pulmonary arterial hypertension | Prof David S Celermajer | Completed | No outcome recorded |
| Comparator or background therapy18 trials | ||||||
| Phase 0 | NCT04770155 Comparator | May → Sep 2021 | vascular insufficiency disorder | University of Mississippi Medical Center | Terminated | No outcome recorded |
| Phase 1 | NCT05072106 Comparator | Jan 2021 → Jan 2022 | neoplasm | PharmaMar | Completed | No outcome recorded |
| Phase 2 | NCT01827059 Comparator | Oct 2013 → Feb 2018 | congenital heart disease, pulmonary arterial hypertension | Academic Medical Center - University of Amsterdam | Unknown | No outcome recorded |
| Phase 2 | NCT01518595 Comparator | Oct 2011 → Apr 2014 | cirrhosis of liver, hepatopulmonary syndrome | Medical University of Vienna | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01292551 Comparator | Feb 2011 → Mar 2013 | hypoplastic left heart syndrome, tricuspid atresia | Rigshospitalet, Denmark | Completed | No outcome recorded |
| Phase 2 | NCT00825266 Comparator | Sep 2008 → May 2010 | pulmonary arterial hypertension | Stanford University | Terminated | No outcome recorded |
| Phase 2/3 | NCT00581607 Comparator | Apr 2008 → Oct 2012 | pulmonary arterial hypertension, sarcoidosis | University of Cincinnati | Completed | No outcome recorded |
| Phase 3 | NCT04039464 Comparator | Aug 2022 → Dec 2025 | pulmonary arterial hypertension | Johns Hopkins University | Completed | No outcome recorded |
| Phase 3 | NCT01824290 Background | Feb 2014 → Mar 2019 | pulmonary arterial hypertension | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT01218607 Comparator | Oct 2010 → Mar 2014 | atrial septal defect, ostium secundum type | Universitaire Ziekenhuizen KU Leuven | Completed | No outcome recorded |
| Phase 3 | NCT00820352 Comparator | Jan 2009 → Jun 2014 | diastolic heart failure, pulmonary hypertension | University Teaching Hospital Hall in Tirol | Completed | No outcome recorded |
| Phase 3 | NCT00302211 Background | Feb 2006 → Dec 2007 | pulmonary hypertension | Actelion | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT06317805 Background | Dec 2023 → Jun 2027 expected | pulmonary arterial hypertension | AOP Orphan Pharmaceuticals AG | Recruiting | No outcome recorded |
| Phase 4 | NCT03053739 Comparator | Dec 2016 → Dec 2017 | pulmonary arterial hypertension | Post Graduate Institute of Medical Education and Research, Chandigarh | Unknown | No outcome recorded |
| Phase 4 | NCT01449253 Comparator | Aug 2011 → Jul 2013 | pulmonary hypertension owing to lung disease and/or hypoxia | All India Institute of Medical Sciences | Unknown | No outcome recorded |
| Phase 4 | NCT00637065 Comparator | Apr 2008 → Apr 2010 | idiopathic pulmonary fibrosis, non-specific interstitial pneumonia, pulmonary hypertension | Royal Brompton & Harefield NHS Foundation Trust | Unknown | No outcome recorded |
| Phase 4 | NCT00323297 Background | Sep 2006 → Aug 2013 | pulmonary arterial hypertension | Viatris Inc. | Completed | Missed primary |
| — | NCT01378845 Comparator | Jul 2011 → Jun 2015 | Raynaud disease | Christoph Hehrlein | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 9
| Date | Issuer | Release |
|---|---|---|
| 2026-02-18 | Zydus Lifesciences Limited | Regulatory Zydus receives final approval from USFDA for Bosentan tablets for oral suspension, 32 mg zyduslife.com ↗
Zydus Lifesciences Limited (including its subsidiaries/ affiliates, hereafter referred to as “Zydus”) has received final approval from the United States Food and Drug Administration (USFDA) for Bosentan tablets, oral suspension, 32 mg (USRLD: Tracleer® Tablets for Oral Suspension, 32 mg). |
| 2025-02-10 | NATCO Pharma Ltd. | Regulatory NATCO and its alliance partner Lupin announces approval of its Abbreviated New Drug Application (ANDA) for Bosentan Tablets for Oral Suspension (generic of Tracleer®) natcopharma.co.in ↗
NATCO Pharma Limited (BSE: 524816 and NSE: NATCOPHARM) ("NATCO") today announces final approval of its ANDA for Bosentan tablets for oral suspension (TFOS), 32mg, a generic version of Tracleer® by Actelion Pharmaceuticals US Inc. |
| 2025-02-10 | Lupin Limited | Regulatory Lupin and Natco Receive Approval from U.S. FDA for Bosentan Tablets for Oral Suspension lupin.com ↗
they have received an approval from the United States Food and Drug Administration (U.S. FDA) for Natco’s Abbreviated New Drug Application (ANDA) for Bosentan Tablets for Oral Suspension, 32 mg |
| 2023-02-15 | Zydus Lifesciences Limited | Regulatory Zydus receives tentative approval from the USFDA for Bosentan Tablets for Oral Suspension zyduslife.com ↗
Zydus Lifesciences Limited (including its subsidiaries/affiliates hereafter referred to as “Zydus”) has received tentative approval from the United States Food and Drug Administration (USFDA) to market Bosentan Tablets for Oral Suspension, 32 mg (USRLD: Tracleer® Tablets for Oral Suspension). |
| 2020-01-01 | Alembic Pharmaceuticals Ltd. | Regulatory Press Release USFDA Approval Bosentan Tablets, 62.5 mg and 125 mg. alembicpharmaceuticals.com ↗
Alembic Pharmaceuticals announces USFDA Final Approval for Bosentan Tablets, 62.5 mg and 125 mg. |
| 2019-06-04 | NATCO Pharma Ltd. | Regulatory Natco files ANDA for Bosentan 32mg Tablets for the USA market natcopharma.co.in ↗
Natco Pharma Limited (NSE: NATCOPHARM; BSE: 524816) is pleased to announce its submission of an Abbreviated New Drug Application (ANDA) with Para IV certification with U.S. Food and Drug Administration (FDA) for the generic version of Bosentan 32mg tablets for oral suspension. |
| 2019-05-02 | NATCO Pharma Ltd. | Regulatory Natco & its alliance partner Lupin receive FDA approval for generic Bosentan Tablets natcopharma.co.in ↗
Natco Pharma Limited (NSE: NATCOPHARM; BSE: 524816) is pleased to announce the final approval of Abbreviated New Drug Application (ANDA) from the U.S. Food and Drug Administration (FDA) for Bosentan tablets in the strengths of 62.5 mg and 125 mg. |
| 2019-04-30 | Zydus Lifesciences Limited | Regulatory Zydus receives final approval from the USFDA for Bosentan Tablets & Trientine Hydrochloride Capsules zyduslife.com ↗
Zydus Cadila has received the final approval from the USFDA to market Bosentan Tablets USP (US RLD – Tracleer® Tablets), 62.5 mg and 125 mg and Trientine Hydrochloride Capsules USP (US RLD - Syprine® Capsules), 250 mg. |
| 2019-04-30 | Lupin Limited | Regulatory Lupin in alliance with Natco receives FDA approval for Bosentan Tablets lupin.com ↗
announced that it has received approval for Bosentan Tablets, 62.5 mg and 125 mg, from the United States Food and Drug Administration (FDA) |
All press releases naming this drug 12 releases
Evidence & citations 14 cited values
Every value below carries the sentence it was read from. 104 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | bosentan | “All patients will receive standard of care double oral background treatment consisting of one Phosphodiesterase type 5 inhibitor (i.e., tadalafil or sildenafil) and one...” NCT06317805 ↗101“endothelin receptor antagonist, Tracleer (Bosentan), to investigate the effect of Tracleer on tourniquet-associated hypertension” NCT03229694 ↗ “All participants were taking endothelin receptor antagonist (ERA) (such as bosentan, ambrisentan and macitentan).” NCT01824290 ↗ “Tracleer (Bosentan) in Patients With Pulmonary Arterial Hypertension Related to Eisenmenger Physiology” NCT00367770 ↗ “Bosentan 62.5 mg twice daily Uptitrated to 125mg twice daily if tolerated after 4 weeks Total 10 weeks” NCT06432452 ↗ “8 patients will be treat with bosentan at 145 mg per day during 14 days” NCT03841734 ↗ “Bosentan: 125 mg (one film-coated tablet of 125 mg) orally (p.o.)” NCT05072106 ↗ “Participants will be given PO Bosentan 125 mg BD for 4 weeks.” NCT07670091 ↗ “One Bosentan 125 mg tablet” NCT01864863 ↗ “Oral Bosentan” NCT05518422 ↗ |
| Known as | Anhydrous bosentan | ChEMBL registry synonym — accepted as the source's own label CHEMBL957 ↗ |
| Known as | Bosentan (as monohydrate) | ChEMBL registry synonym — accepted as the source's own label CHEMBL957 ↗ |
| Known as | Bosentan anhydrous | ChEMBL registry synonym — accepted as the source's own label CHEMBL957 ↗ |
| Known as | Bosentan hydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL957 ↗ |
| Known as | Bosentan monohydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL957 ↗ |
| Known as | BOSENTAN SODIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL957 ↗ |
| Known as | Bosentan: Tracleer | “Bosentan = Tracleer” NCT01218607 ↗1“Bosentan: Tracleer” NCT01292551 ↗ |
| Known as | RO 47-0203/029 | ChEMBL registry synonym — accepted as the source's own label CHEMBL957 ↗ |
| Known as | Stayveer | ChEMBL registry synonym — accepted as the source's own label CHEMBL957 ↗ |
| Known as | Tracleer | “Bosentan (Tracleer®) is a non-selective endothelin receptor antagonist with dual binding (ETA and ETB) and complete blocking of endothelin-1.” NCT00266162 ↗4“Bosentan (Tracleer 125mg Tabletts), peroral, dose: 500mg for 8 days” NCT00701597 ↗ “Bosentan (Tracleer)” NCT00318175 ↗ |
| Action | Inhibit | “Bosentan (an oral dual ET-1 receptor antagonist)” NCT00071461 ↗ |
| Modality | Other / unclassified | “the endothelin receptor antagonist bosentan” NCT01712997 ↗ |
| Route | Oral | “oral bosentan” NCT00070590 ↗ |